AR108793A1 - Composiciones que comprenden timolol y un agente antiinflamatorio - Google Patents
Composiciones que comprenden timolol y un agente antiinflamatorioInfo
- Publication number
- AR108793A1 AR108793A1 ARP170101656A ARP170101656A AR108793A1 AR 108793 A1 AR108793 A1 AR 108793A1 AR P170101656 A ARP170101656 A AR P170101656A AR P170101656 A ARP170101656 A AR P170101656A AR 108793 A1 AR108793 A1 AR 108793A1
- Authority
- AR
- Argentina
- Prior art keywords
- rosacea
- treatment
- timolol
- topical
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Refiere a combinaciones que comprenden timolol y un compuesto útil para el tratamiento de rosácea seleccionado de ivermectina, metronidazol y praziquantel y al uso de estas combinaciones en el tratamiento tópico de rosácea. Reivindicación 1: Combinación para su uso tópico que comprende (a) timolol o una sal farmacéuticamente aceptable del mismo, y (b) un compuesto activo útil para el tratamiento de rosácea seleccionado de ivermectina, metronidazol, praziquantel y sales farmacéuticamente aceptables de los mismos. Reivindicación 7: Composición farmacéutica adecuada para administración tópica que comprende una combinación según una cualquiera de las reivindicaciones 1 a 5, en la que los componentes (a) y (b) están presentes en la misma formulación. Reivindicación 9: Composición farmacéutica según una cualquiera de las reivindicaciones 7 u 8, en la que la composición es una loción, una crema o un gel. Reivindicación 14: Método de tratamiento de un paciente que padece rosácea, método que comprende administrar por vía tópica a dicho paciente una combinación según una cualquiera de las reivindicaciones 1 a 5 o una composición farmacéutica según una cualquiera de las reivindicaciones 7 a 10. Reivindicación 17: Uso de (a) timolol o una sal farmacéuticamente aceptable del mismo según una cualquiera de las reivindicaciones 1 ó 2 en la fabricación de un medicamento para el tratamiento de rosácea mediante coadministración tópica con (b) un agente antiinflamatorio según una cualquiera de las reivindicaciones 1, 3, 4 ó 5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382279 | 2016-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108793A1 true AR108793A1 (es) | 2018-09-26 |
Family
ID=56148331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101656A AR108793A1 (es) | 2016-06-16 | 2017-06-15 | Composiciones que comprenden timolol y un agente antiinflamatorio |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190231788A1 (es) |
EP (1) | EP3471719A1 (es) |
JP (1) | JP2019518045A (es) |
KR (1) | KR20190018440A (es) |
CN (1) | CN109475532A (es) |
AR (1) | AR108793A1 (es) |
AU (1) | AU2017285258A1 (es) |
BR (1) | BR112018075983A2 (es) |
CA (1) | CA3026625A1 (es) |
EA (1) | EA201990042A1 (es) |
MA (1) | MA45387A (es) |
MX (1) | MX2018015239A (es) |
TW (1) | TW201803569A (es) |
WO (1) | WO2017216309A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024134266A1 (en) * | 2022-12-20 | 2024-06-27 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of dermal and ocular disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
FR2866567A1 (fr) * | 2004-02-20 | 2005-08-26 | Galderma Res & Dev | Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee |
EP1979366A4 (en) * | 2006-01-10 | 2011-05-25 | Ruey J Yu | N- (PHOSPHONOALKYL) -AMINOACES, DERIVATIVES AND COMPOSITIONS AND METHODS OF USE THEREOF |
-
2017
- 2017-06-15 BR BR112018075983A patent/BR112018075983A2/pt not_active Application Discontinuation
- 2017-06-15 CA CA3026625A patent/CA3026625A1/en not_active Abandoned
- 2017-06-15 EP EP17732846.5A patent/EP3471719A1/en not_active Withdrawn
- 2017-06-15 MA MA045387A patent/MA45387A/fr unknown
- 2017-06-15 AU AU2017285258A patent/AU2017285258A1/en not_active Abandoned
- 2017-06-15 US US16/309,814 patent/US20190231788A1/en not_active Abandoned
- 2017-06-15 CN CN201780042810.5A patent/CN109475532A/zh active Pending
- 2017-06-15 EA EA201990042A patent/EA201990042A1/ru unknown
- 2017-06-15 MX MX2018015239A patent/MX2018015239A/es unknown
- 2017-06-15 JP JP2018565406A patent/JP2019518045A/ja active Pending
- 2017-06-15 WO PCT/EP2017/064707 patent/WO2017216309A1/en unknown
- 2017-06-15 KR KR1020187036450A patent/KR20190018440A/ko unknown
- 2017-06-15 AR ARP170101656A patent/AR108793A1/es unknown
- 2017-06-16 TW TW106120189A patent/TW201803569A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3471719A1 (en) | 2019-04-24 |
US20190231788A1 (en) | 2019-08-01 |
MA45387A (fr) | 2019-04-24 |
CN109475532A (zh) | 2019-03-15 |
AU2017285258A1 (en) | 2019-01-24 |
CA3026625A1 (en) | 2017-12-21 |
MX2018015239A (es) | 2019-04-15 |
TW201803569A (zh) | 2018-02-01 |
KR20190018440A (ko) | 2019-02-22 |
BR112018075983A2 (pt) | 2019-04-02 |
JP2019518045A (ja) | 2019-06-27 |
EA201990042A1 (ru) | 2019-05-31 |
WO2017216309A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
CO2018004206A2 (es) | Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d” | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
AR065316A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
NI201100154A (es) | Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis | |
BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |